Radioactive drugs (nuclear medicine) are an inaccessible part of medical diagnosis and treatment, but they have become an important component of modern medicine. The field of the radioactive drug industry has become a hot spot for investment and financing in the pharmaceutical sector in recent years, with multinational companies including Novartis and Eli Lilly making strategic investments. The industrial chain of Chinese nuclear medicine enterprises is becoming increasingly complete. Global research and development of innovative radioactive drugs cover both diagnostic and therapeutic areas, with indications covering various disease areas. In addition to cancer, they also cover mental illnesses, autoimmune diseases, and other fields.
On December 28th, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') officially released the 'Blue Book on the Current Situation and Future Development of China's Radioactive Drug Industry' (hereinafter referred to as the 'Blue Book'). The Blue Book tracks various aspects such as technological development, marketed products, clinical pipelines, favorable policies, market growth, capital enthusiasm, and industrial chain, to display the development context of the industry, analyze the current situation of China's radioactive drug market industry, and predict future industry development trends.
